220 related articles for article (PubMed ID: 21118410)
1. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Keogh A; Strange G; Kotlyar E; Williams T; Kilpatrick D; Macdonald P; Brown K; Pidoux A; Kermeen F; Steele P; Dalton B; Gabbay E
Intern Med J; 2011 Mar; 41(3):235-44. PubMed ID: 21118410
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
[TBL] [Abstract][Full Text] [Related]
3. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
4. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
5. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Porhownik NR; Al-Sharif H; Bshouty Z
Can Respir J; 2008; 15(8):427-30. PubMed ID: 19107243
[TBL] [Abstract][Full Text] [Related]
6. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
[TBL] [Abstract][Full Text] [Related]
7. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
Barst RJ; Beghetti M; Pulido T; Layton G; Konourina I; Zhang M; Ivy DD;
Circulation; 2014 May; 129(19):1914-23. PubMed ID: 24637559
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
9. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
[TBL] [Abstract][Full Text] [Related]
11. Initial dual oral combination therapy in pulmonary arterial hypertension.
Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
[TBL] [Abstract][Full Text] [Related]
12. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
Sitbon O; Jaïs X; Savale L; Cottin V; Bergot E; Macari EA; Bouvaist H; Dauphin C; Picard F; Bulifon S; Montani D; Humbert M; Simonneau G
Eur Respir J; 2014 Jun; 43(6):1691-7. PubMed ID: 24627535
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
14. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Hoeper MM; Markevych I; Spiekerkoetter E; Welte T; Niedermeyer J
Eur Respir J; 2005 Nov; 26(5):858-63. PubMed ID: 16264047
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?
Moonen A; Garsia R; Youssef P; Torzillo P; Corte T; Boehm C; Cordina R; Celermajer D; Lau E
Intern Med J; 2017 Oct; 47(10):1124-1128. PubMed ID: 28560817
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of idiopathic pulmonary arterial hypertension].
Andreassen AK; Gude E; Solberg OG; Ueland T
Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1285-8. PubMed ID: 21725387
[TBL] [Abstract][Full Text] [Related]
17. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
[TBL] [Abstract][Full Text] [Related]
18. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
[TBL] [Abstract][Full Text] [Related]
19. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.
Lopez-Meseguer M; Berastegui C; Monforte V; Bravo C; Domingo E; Roman A
Transplant Proc; 2013; 45(6):2347-50. PubMed ID: 23953548
[TBL] [Abstract][Full Text] [Related]
20. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
Hatano M; Yao A; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2011; 52(4):233-9. PubMed ID: 21828950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
